塞德斯医疗 CLDX 深 沪
等待开盘 02-10 09:30:00 美东时间
24.81
+1.050
+4.42%
华盛通- 最 高24.88
- 今 开23.74
- 成交量 45.40万股
- 最 低 23.12
- 昨 收 23.76
- 总市值 16.49亿
- 52周最高 30.50
- 市盈率 静 --
- 换手率 0.68%
- 52周最低 14.40
- 委 比 -46.93%
- 总股本 6644.95万
- 历史最高 582.60
- 量 比 0.54
- 振 幅 7.41%
- 历史最低 1.50
- 每 手 1
- 风险率 3.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Celldex Therapeutics nimmt an mehreren internationalen Investorenkonferenzen teil
Celldex Therapeutics nimmt an mehreren internationalen Investorenkonferenzen teil Celldex Therapeutics Inc. wird am 11. Februar 2026 um 15:30 Uhr ET am Guggenheim Emerging Outlook: Biotech Summit 2026 teilnehmen, am 4. März 2026 um 9:10 Uhr ET an der TD Cowen 46th Annual Health Care Conference und a
02-09 21:01
Celldex to Present at Upcoming Investor Conferences
Celldex announced that its management will participate in fireside chats at three upcoming investor conferences: the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, TD Cowen 46th Annual Health Care Conference on March 4, and the Leerink Global Healthcare Conference on March 10. Live webcasts and 90-day replay access will be available on the "Events & Presentations" page of Celldex's Investors section. Celldex focuses on advancing...
02-09 13:01
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Barclays Maintains Underweight on Celldex Therapeutics, Raises Price Target to $24
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and raises the price target from $21 to $24.
2025-12-18 01:38
Celldex Initiates Global Phase 3 Trial To Establish Efficacy And Safety Of Barzolvolimab In Adult Patients With ColdU And SD Who Remain Symptomatic Despite H1 Antihistamine Treatment
No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical benefit in patients in
2025-12-09 21:10
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
Barclays Maintains Underweight on Celldex Therapeutics, Lowers Price Target to $21
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and lowers the price target from $25 to $21.
2025-11-11 23:03
Celldex Therapeutics Q3 EPS $(1.01) Misses $(0.91) Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.91) by 10.87 percent. This is a 57.81 percent decrease over losses of $(0.64) per share
2025-11-11 05:46
Celldex to Present at Upcoming Investor Conferences
Celldex announced that its management will participate in fireside chats at three upcoming investor conferences: the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11 at 10:00 am ET, the TD Cowen Immunology & Inflammation Summit on November 13 at 9:30 am ET, and the 8th Annual Evercore Healthcare Conference on December 2 at 3:00 pm ET. Live webcasts and 90-day replays will be available on the Events & Presentations page of Cel...
2025-11-07 13:01
Celldex Releases Phase 1 Results For Its Bispecific Antibody CDX-622 Showing Drug Was Well Tolerated, Showed Favorable Pharmacokinetics, And Led To Rapid, Sustained Reductions In Serum Tryptase, Confirming Effective Mast Cell Inhibition
Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and
2025-10-31 04:14
